Lim Dong-Yoon, Lee Yong-Gyoon, Kim Il-Hwan
Department of Pharmacology, College of Medicine, Chosun University, Kwangju, Korea.
Arch Pharm Res. 2002 Aug;25(4):511-21. doi: 10.1007/BF02976611.
The purpose of this study was to determine whether bromocriptine affects the catecholamines (CA) secretion evoked in isolated perfused rat adrenal glands, by cholinergic stimulation, membrane depolarization and calcium mobilization, and to establish the mechanism of its action. The perfusion of bromocriptine (1-10 microM) into an adrenal vein, for 60 min, produced relatively dose-dependent inhibition in the secretion of catecholamines (CA) evoked by acetylcholine (ACh, 5.32 mM), DMPP (100 microM for 2 min), McN-A-343 (100 microM for 2 min), cyclopiazonic acid (CPA, 10 microM for 4 min) and Bay-K-8644 (10 microM for 4 min). High K+ (56 mM)-evoked CA release was also inhibited, although not in a dose-dependent fashion. Also, in the presence of apomorphine (100 microM), which is also known to be a selective D2-agonist, the CA secretory responses evoked by ACh, high potassium, DMPP, McN-A-343, Bay-K-8644 and cyclopiazonic acid were also significantly depressed. However, in adrenal glands preloaded with bromocriptine (3 microM) in the presence of metoclopramide (15 microM), a selective D2-antagonist, the CA secretory responses evoked by ACh, high potassium, DMPP, McN-A-343, Bay-K-8644 and cyclopiazonic acid considerably recovered as compared to that of bromocriptine only. Taken together, these results suggest that bromocriptine can inhibit the CA secretion evoked by stimulation of cholinergic receptors, as well as by membrane depolarization, in the perfused rat adrenal medulla. It is thought this inhibitory effect of bromocriptine may be mediated by inhibiting the influx of extracellular calcium and the release from intracellular calcium stores, through the activation of dopaminergic D2-receptors located in the rat adrenomedullary chromaffin cells. Furthermore, these findings also suggest that the dopaminergic D2-receptors may play an important role in regulating adrenomedullary CA secretion.
本研究的目的是确定溴隐亭是否会影响离体灌注大鼠肾上腺中由胆碱能刺激、膜去极化和钙动员所诱发的儿茶酚胺(CA)分泌,并确立其作用机制。将溴隐亭(1 - 10微摩尔)灌注到肾上腺静脉中60分钟,对由乙酰胆碱(ACh,5.32毫摩尔)、二甲基苯基哌嗪(DMPP,100微摩尔,作用2分钟)、 McN - A - 343(100微摩尔,作用2分钟)、环匹阿尼酸(CPA,10微摩尔,作用4分钟)和Bay - K - 8644(10微摩尔,作用4分钟)诱发的儿茶酚胺(CA)分泌产生相对剂量依赖性抑制。高钾(56毫摩尔)诱发的CA释放也受到抑制,尽管不是呈剂量依赖性。此外,在同样已知为选择性D2 - 激动剂的阿扑吗啡(100微摩尔)存在的情况下,由ACh、高钾、DMPP、McN - A - 343、Bay - K - 8644和环匹阿尼酸诱发的CA分泌反应也显著降低。然而,在存在选择性D2 - 拮抗剂甲氧氯普胺(15微摩尔)的情况下,预先用溴隐亭(3微摩尔)加载的肾上腺中,与仅用溴隐亭相比,由ACh、高钾、DMPP、McN - A - 343、Bay - K - 8644和环匹阿尼酸诱发的CA分泌反应有相当程度的恢复。综上所述,这些结果表明溴隐亭可以抑制灌注大鼠肾上腺髓质中由胆碱能受体刺激以及膜去极化所诱发的CA分泌。据认为,溴隐亭的这种抑制作用可能是通过激活大鼠肾上腺髓质嗜铬细胞中的多巴胺能D2受体,抑制细胞外钙内流和细胞内钙库释放来介导的。此外,这些发现还表明多巴胺能D2受体可能在调节肾上腺髓质CA分泌中起重要作用。